Navigation Links
Sinovac Reports Unaudited Second Quarter Financial Results
Date:8/14/2014

s_span">-

-

-

-Total sales12,090

100.0%

17,452

100.0%Cost of goods sold3,025

25.0%

3,861

22.1%Gross profit9,065

75.0%

13,591

77.9%In the second quarter 2014, total sales were $12.1 million, a decrease of 30.7% from $17.5 million during the same period in 2013. This decrease was primarily due to softer demand in the private vaccine market. China's CDCs have been also more conservative in their vaccination programs. Nevertheless, the Company achieved record sales in the second quarter of 2013, which resulted in a higher basis for year-over-year comparison.

Gross profit was $9.1 million in the second quarter 2014, compared to $13.6 million in the prior year period. Gross margin decreased to 75.0% from 77.9% in the prior year period. The slight decrease in gross margin is attributable to idle capacity in the Company's influenza facility during the second quarter, which was charged to cost of goods sold.

Selling, general and administrative expenses for the second quarter 2014 were $8.6 million, compared to $8.8 million in the same period of 2013.

R&D expenses for the second quarter of 2014 were $3.3 million, a $1.2 million increase over the same period in 2013. These expenses are primarily related to the continued advancement of pipeline vaccine candidates, including sIPV, EV71, PPV, and varicella vaccine.

Net loss attributable to common st
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results
2. Sinovac to Participate in UBS Asia Healthcare CEO Summit in November 2013
3. Sinovac Biotech Receives GMP Certification for Mumps Vaccine Production Facility
4. Sinovac to Present at 55th Annual BioPharma China Convention 2012 - Vaccine & Antibody Focus
5. Sinovac Announces Resignation of Chup Hung Mok from Board of Directors
6. Pressure BioSciences, Inc. Reports Second Quarter 2014 Financial Results and Provides Business Update
7. RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2014
8. Synthetic Biologics Reports Second Quarter 2014 Financial Results and Operational Highlights
9. MarketResearch.com: New Biotechnology Market Research Reports Added to Kalorama Information Knowledge Center
10. GenVec Reports Second Quarter 2014 Financial Results
11. BioSpecifics Technologies Corp. Reports Second Quarter 2014 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014 Today, TiFiber, Inc. ... production facility and future company headquarters in Fort ... new materials that safely and effectively control dangerous ... of its historic, strong support for manufacturing, but ... leading edge, technology-based companies such as TiFiber. ...
(Date:12/19/2014)... Biddeford, ME (PRWEB) December 18, 2014 ... founding director of the Center for Excellence in the ... of New England, has been selected as a member ... He is the first neuroscientist from Maine to receive ... a nonprofit organization supported entirely by the Dana Foundation. ...
(Date:12/19/2014)... (PRWEB) December 18, 2014 iLab Solutions, ... the appointment of Siri Bryant as the new Director ... Director of Core Implementations. These two new leadership positions ... customer service by ensuring that iLab continues to meet ... the last four years, iLab has been deployed at ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 The ... to the rising ageing population and technological innovations ... and nutraceutical industries are catalysing the growth of ... @ http://www.marketsandmarkets.com/Market-Reports/empty-capsules-market-218018190.html , Scope of Report ... as well as new entrants/smaller firms to gauge ...
Breaking Biology Technology:Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 2Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 4UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 2UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 3iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4
... Stock Exchange Symbol: MS, EDMONTON, April 15 /PRNewswire-FirstCall/ ... the treatment of multiple sclerosis (MS), today,announced that Mr. ... EQUITIES Magazine,s 57th Anniversary Spring Conference., WHEN: ... AM (Eastern Time), WHERE: The ...
... SGX Pharmaceuticals, Inc.,(Nasdaq: SGXP ) presented abstract #4844 ... Cancer Research (AACR) in San Diego. The poster,entitled "SGX523, ... tyrosine kinase (MET), inhibits growth of human glioblastoma,tumors in ... session,entitled Small Molecule Kinase Inhibitors 1 in Exhibit Hall ...
... Therapeutics,Inc. (Nasdaq: CVTX ) announced today that ... to $185 million in exchange for rights to ... sales of Lexiscan(TM),(regadenoson) injection. CV Therapeutics received $175 ... a potential future milestone payment,of $10 million., ...
Cached Biology Technology:BioMS Medical to present at EQUITIES Conference 2SGX Presents Preclinical MET Data at AACR 2SGX Presents Preclinical MET Data at AACR 3CV Therapeutics Announces $185 Million Transaction with TPG-Axon Capital for Half of Royalty for Lexiscan(TM) (regadenoson) Injection 2CV Therapeutics Announces $185 Million Transaction with TPG-Axon Capital for Half of Royalty for Lexiscan(TM) (regadenoson) Injection 3
(Date:12/19/2014)...   LaunchKey , the first decentralized mobile authentication ... of Things era, today announced the close of $3 ... led by Metamorphic Ventures with participation from ENIAC Ventures, ... others.  LaunchKey has raised $4 million to date, and ... and bring LaunchKey to market in 2015. ...
(Date:12/17/2014)... 2014 Valencell, a leader in performance biometric ... to industry leaders such as Intel, Jabra, Atlas, and ... wearable products. These products will be showcased at CES ... Vegas . "Our partners choose ... robust – with the clinical data to back it ...
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... to their offering. One major ... technology. With continuous advances in technology, it is ... standard that meets the needs and expectations of ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... HOUSTON (Nov. 8, 2012) Four young scientists ... Research Institute (NSBRI). Through this two-year program, they conduct ... during long-duration spaceflights. In addition to receiving mentorship from ... are members of one of NSBRI,s seven research teams. ...
... in removing the extra copy of chromosome 21 in ... In Down syndrome, the body,s cells contain three ... A triplicate of any chromosome is a serious ... one-quarter of pregnancy loss from spontaneous miscarriages, according to ...
... 2012  Genomic Health, Inc. (Nasdaq: GHDX ) today ... Officer, Chairman and President will present at the following conferences ... on Thursday, November 15, 2012 at 2:00 p.m. Mountain Time ... Jaffray Healthcare Conference on Tuesday, November 27 at 2:30 p.m. ...
Cached Biology News:Space research institute awards postdoctoral fellowships to 4 scientists 2Extra chromosome 21 removed from Down syndrome cell line 2Extra chromosome 21 removed from Down syndrome cell line 3Genomic Health to Present at Two Upcoming Investor Conferences 2Genomic Health to Present at Two Upcoming Investor Conferences 3
HSD17B3 Immunogen: HSD17B3 (NP_000188, 29 a.a. ~ 120 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rad51, N-terminal...
Phospho-mu-Opioid Receptor (Ser375) Antibody...
Rabbit polyclonal to WWOX8 ( Abpromise for all tested applications). entrezGeneID: 51741 SwissProtID: Q9NZC7-8...
Biology Products: